Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Profit After Tax (2019 - 2025)

Historic Profit After Tax for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$32.2 million.

  • C4 Therapeutics' Profit After Tax fell 3040.62% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 1286.87%. This contributed to the annual value of -$105.3 million for FY2024, which is 2051.62% up from last year.
  • As of Q3 2025, C4 Therapeutics' Profit After Tax stood at -$32.2 million, which was down 3040.62% from -$26.0 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Profit After Tax ranged from a high of -$15.7 million in Q4 2021 and a low of -$37.2 million during Q4 2022
  • Moreover, its 5-year median value for Profit After Tax was -$27.4 million (2022), whereas its average is -$28.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 13752.07% in 2022, then surged by 5068.2% in 2024.
  • C4 Therapeutics' Profit After Tax (Quarter) stood at -$15.7 million in 2021, then plummeted by 137.52% to -$37.2 million in 2022, then grew by 6.58% to -$34.8 million in 2023, then increased by 0.54% to -$34.6 million in 2024, then grew by 6.96% to -$32.2 million in 2025.
  • Its Profit After Tax was -$32.2 million in Q3 2025, compared to -$26.0 million in Q2 2025 and -$26.3 million in Q1 2025.